Značaj Galaktina-3 i N-terminalnog pro B-tipa natruretskog peptida u predviđanju atrijalne fibrilacije nakon kardiohirurške procedure

Bimarkeri i postoperativna atrijalna fibrilacija

  • Nikola Mladenović Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Ranko Zdravković Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija
  • Lazar Velicki Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija
  • Vanja Dljević Todić Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija
  • Mirko Todić Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija
  • Srđan Maletin Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija
  • Aleksandra Mladenović Institut za kardiovaskularne bolesti Vojvodine, Sremska Kamenica, Srbija
  • Nemanja Petrović Institut za kardiovaskularne bolesti Vojvodine, Sremska Kamenica, Srbija
  • Bogdan Okiljević Institut za kardiovaskularne bolesti Dedinje, Beograd, Srbija
  • Valentina Nikolić Univerzitet Niš, Medicinski fakultet, Niš, Srbija
  • Milan Pavlović Univerzitet Niš, Medicinski fakultet, Niš, Srbija
  • Dane Krtinić Univerzitet Niš, Medicinski fakultet, Niš, Srbija
  • Aleksandar Nikolić Univerzitet Niš, Medicinski fakultet, Niš, Srbija
  • Marko Gmijović Univerzitet Niš, Medicinski fakultet, Niš, Srbija
  • Aleksandar Kamenov Univerzitet Niš, Medicinski fakultet, Niš, Srbija
DOI: https://doi.org/10.5937/jomb0-47001
Ključne reči: Postoperativna atrialna fibrilacija, Kardiohirurgija, Galektin-3, NT-proBNP

Sažetak


Uvod: Postoperativna atrijalna fibrilacije (POAF) je učestala komplikacija nakon kardiohirurških procedura. Povezana je sa produženim hospitalnim lečenjem, povećanim morbiditetom, stopom mortaliteta i finansiskim troškovima. Cilj rada je bio da se utvrdi povezanost nivoa Galektina-3 i N-terminalnog pro-B-tipa natriuretskog peptida (NT-proBNP) sa POAF nakon kardiohirurške operacije.

Pacijenti i metode: Prospektivna studija obuhvata bolesnike starosti od 18-85 godina, hospitalizovanih radi elektivne operacije aorto koronarnog bajpasa (CABG) ili CABG sa zamenom aortnog zaliska. Nivoi Galektina-3 i NT-proBNP iz krvi mereni su preoperativno i postoperativnog 1. i 7. dana.

Rezultati: U istraživanju je uključeno 103 bolesnika. PAOF je zabeležena kod 45 bolesnika. Prosečna starost bolesnika kod kojih je registrovan POAF bila je 68,8 godina, dok je kod ostalih bila 65,5 godina (n=0,028). Nivoi Galektina-3 i NT-proBNP nisu se razlikovali kod bolesnika koji su razvili POAF, a ni kod onih kojima nije registrovana POAF u sva tri merenja. Promene nivoa Galektin-3 prvog postoperativnog dana imaju statistički značajnu vrednost za predviđanje POAF (AUC=0.627 [0.509-0.745], p<0.05). Smanjenje nivoa Galektina-3 prvog postoperativnog dana za preko 17% dovodi do povećanog rizika od razvoj POAF .

Zaključak: Preoperativne vrednosti Galektina-3 i NT-proBNP nisu povezani sa razvojem POAF nakon kardiohirurške intervencije. Jedina povezanost koju smo zabeležili je da smanjene vrednosti Galektina-3 prvog postoperativnog dana za preko 17% mogu biti prediktor za POAF.

Biografije autora

Ranko Zdravković, Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija

Asistent na predmetu Anesteziologija sa reanimatologijom.

Lazar Velicki, Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija

Profesor na katedri za Hirurgiju.

Vanja Dljević Todić, Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija

Asistent na katedri za Internu medicinu.

Mirko Todić, Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija

Asisten na katedri za Internu medicinu

Srđan Maletin, Univeryitet Novi Sad, Medicinski fakultet, Novi Sad, Srbija

Asistent na katedri za Internu medicinu

Aleksandra Mladenović, Institut za kardiovaskularne bolesti Vojvodine, Sremska Kamenica, Srbija

Lekar na klinici za Kardiovaskularnu hirurgiju

Nemanja Petrović, Institut za kardiovaskularne bolesti Vojvodine, Sremska Kamenica, Srbija

Lekar na Klinici za Kardiovaskularnu hirurgiju.

Bogdan Okiljević, Institut za kardiovaskularne bolesti Dedinje, Beograd, Srbija

Kardiohirurg

Valentina Nikolić, Univerzitet Niš, Medicinski fakultet, Niš, Srbija

Profesor na katedri za Farmakologiju

Milan Pavlović, Univerzitet Niš, Medicinski fakultet, Niš, Srbija

Profesor na katedri Interne medicine

Dane Krtinić, Univerzitet Niš, Medicinski fakultet, Niš, Srbija

Docent na katedri za Farmakologiju

Aleksandar Nikolić, Univerzitet Niš, Medicinski fakultet, Niš, Srbija

Asistent na katedri za Anestezilogiju i renimatologiju

Marko Gmijović, Univerzitet Niš, Medicinski fakultet, Niš, Srbija

Asistent na katedri za Hirurgiju

Aleksandar Kamenov, Univerzitet Niš, Medicinski fakultet, Niš, Srbija

Asistent na katedri ya Hirurgiju

Reference

1.         Obrenović-Kirćanski B, Orbović B, Vraneš M, Parapid B, Kovačević-Kostić N, Velinović M, at al. Atrial fibrillation after coronary artery bypass surgery: Possibilities of prevention. Srp Arh Celok Lek 2012; 140: 521-527.


2.         Halonen J, Kärkkäinen J, Jäntti H, Martikainen T, Valtola A, Ellam S, at al. Prevention of Atrial Fibrillation After Cardiac Surgery: A Review of Literature and Comparison of Different Treatment Modalities. Cardiol Rev 2022; Online ahead of print.


3.         Charitakis E, Tsartsalis D, Korela D, Stratinaki M, Vanky F, Charitos EI, at al. Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses. Open Heart 2022; 9: e002074.


4.         Cai M, Schotten U, Dobrev D, Heijman J. Atrial fibrillation substrate development before, during and after cardiac surgery: Who is to blame for late post-operative atrial fibrillation? Int J Cardiol 2022; 365: 44-46.


5.         Hernández-Romero D, Vílchez JA, Lahoz Á, Romero-Aniorte AI, Jover E, García-Alberola A, at al. Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. Sci Rep 2017; 7: 40378.


6.         Werhahn SM, Becker C, Mende M, Haarmann H, Nolte K, Laufs U, at al. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Failure 2022; 9: 100–109.


7.         Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, at al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498.


8.         Rezk M, Taha A, Nielsen SJ, Gudbjartsson T, Bergfeldt L, Ahlsson A, at al. Clinical Course of Postoperative Atrial Fibrillation After Cardiac Surgery and Long-term Outcome. Ann Thorac Surg 2022; 114:2209-2215.


9.         Fleet H, Pilcher D, Bellomo R, Coulson TG. Predicting atrial fibrillation after cardiac surgery: a scoping review of associated factors and systematic review of existing prediction models. Perfusion 2023; 38: 92-108.


10.       Erdem K, Kurtoglu E, Oc M, Oc B, Ilgenli TF, Unlu A, at al. The plasma galectin-3 level has high specificity and sensitivity for predicting postoperative atrial fibrillation after coronary artery bypass surgery. Eur Rev Med Pharmacol Sci 2022; 26:9072-9078.


11.       Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules. 2021; 12:46.


12.       Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022; 27: 625-643.


13.       Tian L, Chen K, Han Z. Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis. Cardiol Res Pract 2020; 2020: 7614327.


14.       Richter B, Koller L, Hofer F, Kazem N, Hammer A, Silbert BI, at al. Galectin-3 is an independent predictor of postoperative atrial fibrillation and survival after elective cardiac surgery. Heart Rhythm 2022; 19: 1774-1780.


15.       Patel DM, Thiessen-Philbrook H, Brown JR, McArthur E, Moledina DG, Mansour SG, at al. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American Heart Journal 2020; 220: 253-263.


16.       Polineni S, Parker DM, Alam SS, Thiessen-Philbrook H, McArthur E, DiScipio AW, at al. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery. J Am Heart Assoc 2018; 7: e008371.


17.       Gong M, Cheung A, Wang QS, Li G, Goudis CA, Bazoukis G, at al. Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis. Journal of Clinical Laboratory Analysis. 2020; 34: e23104.


18.       Xu Z, Qian L, Zhang L, Gao Y, Huang S. Predictive value of NT-proBNP, procalcitonin and CVP in patients with new-onset postoperative atrial fibrillation after cardiac surgery. Am J Transl Res 2022; 14: 3481-3487.


19.       Gasparovic H, Burcar I, Kopjar T, Vojkovic J, Gabelica R, Biocina B, at al. NT-pro-BNP, but not C-reactive protein, is predictive of atrial fibrillation in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg 2010; 37: 100-105.

Objavljeno
2023/12/12
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2023 Nikola Mladenovic, Ranok Zdravkovic, Lazar Velicki, Vanja Drljevic Todic, Mirko Todic, Srdjan Maletin, Aleksandra Mladenovic, Nemanja Petrovic, Bogdan Okiljevic, Valentina Nikolić, Milan Pavlovic, Dane Krtinic, Aleksandar Nikolic, Marko Gmijovic, Aleksandar Kamenov

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.